Latest filing published 19 Feb 2026 for GERON CORP.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Michelle Robertson (finance chief) discloses dealings in 4 companies, chiefly Editas Medicine, Inc., Momenta Pharmaceuticals Inc and Geron Corp. In total, 30 filings cover trades dated from 12 February 2019 to 18 February 2026.
No open-market purchase appears, only 17 sales worth €637k. Other entries cover 7 share grants and 5 option exercises. Since January 2026: no purchases and 1 sale on the market.
On 19 February 2026 came the latest disclosure, an open-market sale for €16k in Geron Corp. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
16 of 16 declarations